UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

February 13, 2024

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.

February 13, 2024

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

February 13, 2024

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.

February 01, 2024

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

January 29, 2024

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

January 26, 2024

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

January 24, 2024

Nicholas P. McAndrew, MD, MSCE, discusses the evolution of the treatment armamentarium for HER2-positive breast cancer, including the HER2CLIMB-02 trial.

January 23, 2024

Nicholas P. McAndrew, MD, MSCE, discusses the impact of the phase 3 KATHERINE trial in patients with HER2-positive breast cancer.

January 03, 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

December 27, 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

December 27, 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

December 20, 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

December 20, 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

December 15, 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

December 15, 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

December 10, 2023

The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy in younger and older patients with hematologic malignancies, according to data from a phase 1b study.

December 06, 2023

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

December 06, 2023

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

November 29, 2023

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

November 29, 2023

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.